IONTAS offers a proprietary technology enabling the construction of massive libraries of stable cell lines displaying human antibodies on their surface. As well as generating an abundance of therapeutic antibody leads, the technology also addresses “developability” issues early in discovery thereby increasing the likelihood of successful progress through the development process.   
   
IONTAS use gene editing technology to efficiently direct site-specific integration of antibody genes into a single locus within the mammalian cell genome. This enables construction of libraries of tens of millions of monoclonal stable cell lines displaying IgG-formatted antibodies on their surface. Using flow cytometry many millions of clones can be screened directly for high affinity and specificity. The technology can also identify and avoid clones with potential biophysical liabilities which could otherwise lead to costly delays or even product failure.   
   
The technology also enables chain shuffling and affinity maturation as part of the screening process allowing the identification of antibodies with high affinities and/or improved developability profiles.